NCT06674460View on ClinicalTrials.gov

Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease

PHASE3RecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2028

Conditions
Cerebral Small Vessel DiseaseIschemic Stroke
Interventions
DRUG

Edaravone Dexborneol Sublingual Tablets

One tablet of Edaravone Dexborneol Sublingual Tablet (containing 30mg Edaravone and 6mg Dexborneol) to be taken sublingually, twice daily.

DRUG

Placebo

One placebo tablet, to be taken sublingually, twice daily

Trial Locations (1)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER